CJC-1295 (No DAC) 10MG

CJC-1295 is a synthetic peptide analog of the growth hormone-releasing hormone (GHRH) analog GHRP-6. In the research setting, it is utilized for its ability to stimulate the release of growth hormone and IGF-1, which can be important in the study of hormone regulation, aging, metabolic processes, and potential therapeutic interventions. This product is presented in its decanoate-free (No DAC) form, allowing for more controlled administration in experimental settings.

Research Context

CJC-1295 has been extensively studied as a tool in both academic and industrial research to investigate growth hormone dynamics, aging-related physiological changes, and metabolic health. Due to its specificity in stimulating growth hormone secretion, it serves as a valuable model compound for studying the hypothalamic-pituitary axis and potential biomarkers or therapeutic targets. Importantly, its use is limited to research environments where proper experimental controls and ethical oversight are maintained.

Research Overview

CJC-1295 operates through activation of the growth hormone secretagogue receptor (GHSR) in the hypothalamus. By binding to this receptor, it elicits a cascade of endocrine responses that include the release of growth hormone (GH) from the pituitary gland, which subsequently enhances insulin-like growth factor-1 (IGF-1) production in peripheral tissues. The absence of decanoate (DAC) esterification in this formulation means that the compound may exhibit a more rapid clearance from the body, making it suitable for short-term pharmacokinetic studies or acute dose-response experiments.

Key Research Focus Areas

• Hormonal Regulation: Investigation of GH/IGF-1 axis modulation, including effects on muscle mass, bone density, and metabolism.
• Metabolic Studies: Evaluation of CJC-1295’s impact on glucose tolerance, insulin sensitivity, and lipolysis under controlled research conditions.
• Aging Research: Examination of potential anti-aging mechanisms, including telomere maintenance and cellular turnover, in experimental animal models.
• Pharmacokinetics and Toxicology: Assessment of drug metabolism, receptor binding affinity, and systemic clearance to inform dosing protocols in research settings.
• Comparative Analysis: Contrasting effects of CJC-1295 (No DAC) with its esterified counterpart (e.g., DAC-containing forms) to study metabolic stability and bioavailability.

Safety and Compliance

This product is intended solely for use in accredited research institutions and laboratories. CJC-1295 (No DAC) 10MG is provided as a research chemical and is not intended for human or animal consumption. Users must adhere to all applicable regulatory guidelines, including those outlined by their local regulatory bodies, and conduct experiments in compliance with established ethical standards. Proper documentation, handling procedures, and disposal protocols are mandatory.